A new study published in the American Journal of Hematology highlighted the value of achieving durable molecular response with ruxolitinib and its consideration in future clinical trials as surrogate endpoints. More news: loom.ly/Ogb3a0k #MPN #MPNsm #MedNews #MedEd

New publication 📝 Post hoc analysis results from the SIMPLIFY-1 trial published in Leukemia & Lymphoma provide new insights for #myelofibrosis, see: loom.ly/urxylbE

A new study published in Leukemia & Lymphoma found that momelotinib was beneficial over ruxolitinib irrespective of baseline hemoglobin levels in patients with myelofibrosis 📝 More news: mpn-hub.com #myelofibrosis #MedNews #MedEd

New publication 📝 Phase II results published in AmericanJournalofHematology provide new insights for #EssentialThrombocythemia, see: loom.ly/3t93mtc

A new study published in AmericanJournalofHematology found that a twice-daily low-dose aspirin regimen was superior to the standard once-daily regimen 📝 More news: mpn-hub.com #EssentialThrombocythemia #MedNews #MedEd

New publication 📝 Results from a retrospective analysis published in CMJ provide new insights for #EssentialThrombocythemia, see: loom.ly/J7F7uuI

A new study published in CMJ found that male sex was an independent factor associated with inferior survival in patients with essential thrombocythemia in China📝  More news: mpn-hub.com #EssentialThrombocythemia #MedNews #MedEd

New publication 📝 Results from a retrospective analysis published in Bone Marrow Transplantation provide new insights for #myelofibrosis, see: loom.ly/QKuBhCY #MPN #MPNsm #GvHD

📢 Only 1 day to go!  The MPN Hub will be covering #SOHO2024. 📅 Sep 4–7   📍 Houston, US, and online  We’ll be providing live social media coverage. Keep an eye on our socials to see the latest updates! #mpnsm Society of Hematologic Oncology (SOHO)

CONGRESS | POSTER | #SOHO2024 | Tom Liu presents an exploratory post hoc analysis of the association between Hb improvements and PROs from a pooled analysis of momelotinib phase III SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trails in patients with #myelofibrosis and anemia (N=480).

CONGRESS | POSTER | #SOHO2024 | John Mascarenhas Icahn School of Medicine at Mount Sinai presents the latest data from the phase III MANIFEST-2 study of pelabresib + ruxolitinib (N=214) vs placebo + ruxolitinib (N=216) in pts with JAKi-naïve #myelofibrosis. The study met its primary endpoint, showing a

CONGRESS | POSTER | #SOHO2024 | Prithviraj Bose Prithviraj Bose presents 3-year follow-up data from the phase III PATHFINDER study of avapritinib in pts with advanced systemic #mastocytosis (N=107). The ORR was 73% overall and 87% in treatment-naïve pts, with deep and sustained

A new study published in Bone Marrow Transplantation found that ATLG treatment can improve GRFS in patients with myelofibrosis undergoing allo-HSCT with a matched related or matched unrelated donor 📝  More news: mpn-hub.com #GvHD #MPN #MPNsm #MedNews #MedEd

CONGRESS | #SOHO2024 Laura C. Michaelis Medical College of Wisconsin discusses the goals of therapy in #EssentialThrombocythemia and PolycythemiaVera. Goals for both include managing venous and arterial thrombosis risk by correcting CV risk, providing appropriate anticoagulation, and

CONGRESS | #SOHO2024 Roni Tamari Memorial Sloan Kettering Cancer Center provides and overview of who, when, and how to transplant patients with #myelofibrosis. Tamari emphasizes the consideration of disease-, and patient-related factors, as well as prognostic systems when determining who and when to

CONGRESS | #SOHO2024 Jason Gotlib Stanford Medicine shares data from the phase II FIGHT-203 study of pemigatinib for myeloid/lymphoid neoplasms with FGFR1 rearrangement. Median PFS and OS not reached, Grade ≥3 AEs 83%, CR rate 69%, ORR 78%, CCyR rate 71%. #MPN #MPNsm

CONGRESS | #SOHO2024 Naseema Gangat, Mayo Clinic, discusses accelerated and blast phase #MPN, focusing on diagnosis, risk factors for leukemic transformation, & role of allo-HSCT. She suggests early allo-HSCT for eligible patients once cytoreduction, lower blast % & spleen

New publication 📝 Results from a retrospective analysis published in AmericanJournalofHematology provide new insights for #EssentialThrombocythemia, see: loom.ly/l8deaS0